Back to Search Start Over

PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia

Authors :
Carlos Eduardo dos Santos Ferreira
Francisco Antônio Helfenstein Fonseca
Cristóvão Luis Pitangueira Mangueira
Source :
Einstein (São Paulo), Vol 10, Iss 4, Pp 526-527
Publisher :
Instituto Israelita de Ensino e Pesquisa Albert Einstein.

Abstract

This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.

Details

Language :
English, Portuguese
ISSN :
16794508 and 23176385
Volume :
10
Issue :
4
Database :
Directory of Open Access Journals
Journal :
Einstein (São Paulo)
Publication Type :
Academic Journal
Accession number :
edsdoj.93ad9ab7be404629a2055e56fdfe21d3
Document Type :
article
Full Text :
https://doi.org/10.1590/S1679-45082012000400024